Key Takeaways
• Massachusetts General Hospital (MGH) and Talosix have jointly developed a cutting-edge AI-driven solution, showcasing significant improvements in the rapid identification of leukemia subtypes from pathology reports.
• This collaboration results in simplified patient identification and accelerated eligibility considerations for critical leukemia research. By significantly reducing manual screening times while also increasing identification accuracy, the Talosix AI platform empowers researchers to identify and manage a larger population of eligible patients for potential life-saving clinical trials more efficiently.
• Utilizing advanced Natural Language Processing (NLP), the solution expertly extracts and analyzes key patient data from complex, unstructured records. A user-friendly interface allows for a streamlined review and screening process for faster patient selection in clinical trials, automated data abstraction, and expedited study start-up.
• The collaboration blends MGH's clinical and informatics expertise with Talosix's cutting-edge NLP and ML technologies to expand the application of AI in clinical research, marking a new era in healthcare innovation.
Background
Recognizing the inefficiencies in manually identifying specific leukemia subtypes, the Massachusetts General Hospital (MGH) Adult Leukemia Program, together with the MGH Laboratory of Computer Science (LCS), sought an innovative AI-powered solution. A relationship with Talosix, a leader in clinical research technology, led to a pioneering solution that efficiently processes, analyzes, and summarizes data from unstructured text in pathology reports, significantly reducing manual effort and expediting research processes.
About the Joint Development
“A project of this scale with MGH underscores our commitment to integrating AI in medical research," says Arsenio Valdez, CEO of Talosix. "Our AI-driven platform, combined with MGH's renowned medical knowledge and research capabilities, are set to transform the landscape of healthcare research. Our mission is clear: to get essential treatments to patients as fast as possible.”
As Director of the MGH Laboratory of Computer Science, Dr. Henry Chueh states, “We chose to work with Talosix early on because of its leading capabilities in harnessing the power of AI to accelerate clinical research with measurable cost savings. We’re excited to continue to advance healthcare innovation through our formal collaboration with Talosix.”
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is the original and largest teaching hospital of Harvard Medical School, and a founding member of the Mass General Brigham Integrated Health System. MGH boasts over 1,200 ongoing clinical trials, making it the largest hospital-based research program in the U.S. With an annual research budget exceeding $1 billion, MGH has more than 9,500 researchers across 30+ departments, centers, and institutes. Guided by the needs of its patients, MGH is an internationally recognized academic health center that cares for complex cases in all areas of medicine, with specific centers of excellence in Cancer, Cardiology, Neurosciences, and more.
About Talosix
Talosix, a leader in transforming clinical research with artificial intelligence, focuses on creating AI-powered solutions that enables research teams to do more with less. The globally compliant Talosix platform enhances efficiency across clinical trial phases from study design optimization and startup to patient engagement and clinical data analysis.
Partnering with Fortune 500 companies and innovative research centers, Talosix leverages AI to streamline research, reduce risks, and lower costs. Our platforms are key in advancing clinical research and activating clinical evidence to improve patient care. Learn more about Talosix’s role in evolving clinical trials at www.talosix.com.